We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Horizon Discovery Expands OncoSpan Reference Standards to FFPE and Liquid Biopsy
Product News

Horizon Discovery Expands OncoSpan Reference Standards to FFPE and Liquid Biopsy

Horizon Discovery Expands OncoSpan Reference Standards to FFPE and Liquid Biopsy
Product News

Horizon Discovery Expands OncoSpan Reference Standards to FFPE and Liquid Biopsy


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Horizon Discovery Expands OncoSpan Reference Standards to FFPE and Liquid Biopsy"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Horizon Discovery Group, a company specializing in the application of gene editing and gene modulation for cell line engineering, has announced it has added two new sample formats to its cell-based OncoSpan reference standards for use in the development and validation of workflows for cancer diagnostic assays.

Horizon’s OncoSpan range now includes formalin-fixed, paraffin-embedded (FFPE) and cell-free DNA (cfDNA) formats for mimicking solid tumors and liquid biopsy samples, respectively, in addition to its well-established genomic DNA (gDNA) format. Its cfDNA format offers a large number of variants and genes, over 380 and 152 respectively, to help standardize liquid biopsy testing.

These cell-line derived reference standards closely mimic patient samples and are intended to offer an unlimited and reproducible resource to help ensure consistency during the establishment and validation of diagnostic assays. All three formats are delivered with batch-specific, next-generation sequencing (NGS) data, orthogonally validated by ddPCR, to allow researchers to further validate their analysis pipeline.

Advertisement